| Report Top | Up a Page | Previous | Next | Up a Map | TOC | Page Index | File Index | What's New | Page Bottom |
| Cognigen Corporation - Posters and Presentations : Pre-2006 : 2004 : ICAAC 2004 : Monte Carlo Simulation to Estimate in VITRO susceptibility breakpoints for Moxifloxacin, Gatifloxacin, and Levofloxacin against Staphylococcus Aureus | published Mon, Nov 10, 2008 - 15:27 EST |
Primary Cognigen Author: Alison Meagher, B.S., PharmD.
Event: 44th ICAAC Meeting
October 30–November 2, 2004
Washington Convention Center, Washington, DC
Primary Cognigen Author: Alison Meagher, B.S., PharmD.
Other Contributors:
P.G. Ambrose, Cognigen Corporation, Buffalo, NY
W.A. Craig, University of Wisconsin, Madison, WI
R.N. Jones, The JONES Group, N. Liberty, IA
H. Stass, Bayer HealthCare, Wuppertal, Germany
| Cognigen Corporation - Posters and Presentations : Pre-2006 : 2004 : ICAAC 2004 : Monte Carlo Simulation to Estimate in VITRO susceptibility breakpoints for Moxifloxacin, Gatifloxacin, and Levofloxacin against Staphylococcus Aureus | published Mon, Nov 10, 2008 - 15:27 EST |
| Report Top | Up a Page | Previous | Next | Up a Map | TOC | Page Index | File Index | What's New | Page Top |